News

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, demonstrated encouraging single-agent antitumor activity with a manageable safety profile in the treatment of patients with recurrent small cell lung cancer.

Intentional weight loss in postmenopausal women is associated with a lower endometrial cancer risk, particularly among those with obesity, according to the results of a recent study published in the <em>Journal of Clinical Oncology</em>.<br /> &nbsp;

The latest clinical trial data strongly support anti&ndash;PD-1 therapy as the new second-line treatment standard for patients with microsatellite instability-high metastatic colorectal cancer, says Michael J. Overman, MD.<br /> &nbsp;

The findings from a phase II study of intermittent sunitinib in patients with previously untreated mRCC demonstrate that periodic extended sunitinib treatment breaks are feasible and the clinical efficacy does not seem to be compromised.

There is a significantly large racial disparity in hysterectomy-corrected cervical cancer mortality rates in the United States, according to a&nbsp;recent study published in <em>Cancer.</em>

An immunotherapy-containing regimen was well-tolerated and had a manageable safety profile in patients with microsatellite-high metastatic colorectal cancer, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium<span style="font-size:10.8333px">.</span>

The combination of nilotinib and trametinib proved to be synergistic in <em>BRAF/NRAS</em> wild-type melanoma,&nbsp;according to a recent study presented at the 2016 Society for Melanoma Research Congress.

The combination of dabrafenib and trametinib before and after surgery demonstrated a dramatic improvement in relapse-free survival compared with the standard of care for patients with stage IIIb/c or oligometastatic <em>BRAF</em>-mutant melanoma.

Mohammad Jahanzeb, MD,&nbsp;discusses why researchers must work on identifying targetable mutations in these non-driver adenocarcinomas and shares his insight on other trends and challenges in the field.

As many as one-third of patients with treatment-resistant colorectal cancer attained objective responses with the stemness inhibitor napabucasin plus FOLFIRI chemotherapy with or without bevacizumab.

Melanie E. Royce, MD, PhD,&nbsp;discusses the recent progress in the landscape of HER2-positive breast cancer and what she envisions future treatment approaches will be for patients.&nbsp;

Several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings of an immunohistochemistry analysis of a large patient population.

Joyce A. O&rsquo;Shaughnessy, MD, addresses some of the key issues in breast cancer and shared her expert insight on where TNBC treatment is headed based on recent findings.

H. Jack West, MD,&nbsp;discusses the benefits of EGFR TKIs in NSCLC, challenges with determining optimal sequencing, and potential combinations on the horizon.

A supplemental Biologics License Application for pembrolizumab has been granted a priority review by the FDA for the treatment of patients with locally advanced or metastatic urothelial cancer who progress following platinum-containing chemotherapy.

Pembrolizumab has been granted a priority review by the FDA as a treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

A prospective study is looking at whether breast cancer surgery can be eliminated in patients who respond well to neoadjuvant systemic therapy.

Nivolumab has been granted an accelerated approval by the FDA as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from a phase II CheckMate-275 study.

Patients receiving the same diagnosis, colorectal cancer with synchronous peritoneal metastases (PM), were offered different treatments that led to dramatically different outcomes based upon the institution in which they were diagnosed.

Patients with advanced hepatocellular carcinoma had objective responses and prolonged survival when treated with single-agent nivolumab, data from a dose escalation/expansion trial showed.

Treatment with the PD-1 inhibitor pembrolizumab significantly prolonged overall survival over investigators&rsquo; choice of chemotherapy in patients with recurrent advanced urothelial carcinoma.

The incidence of hand-foot syndrome occurred significantly less often in patients treated with S-1 compared to capecitabine in patients with metastatic colorectal cancer.

Measuring molecular biomarkers after metastasis could inform treatment decisions for women with breast cancer that has spread to the brain.

A pre-planned subgroup analysis of data from the MONALEESA-2 trial demonstrated similar clinical benefit and safety profiles in elderly patients compared to younger patients with HR+/HER2-advanced breast cancer, supporting a paradigm shift in the future medical management of these patients from the current standard of letrozole to combined treatment of letrozole plus ribociclib.

The indication for pembrolizumab has been expanded by the European Commission to include the frontline treatment of patients with metastatic non&ndash;small cell lung cancer that expresses PD-L1 on &ge;50% of cells and does not harbor an EGFR or ALK mutation.

Jenny C. Chang, MD, speaks about the significance of molecular testing in breast cancer and how it will lead to an improvement in treatment approaches in 2017 and beyond.

The risk of progression or death was reduced by 40% with the&nbsp;combination of nab-paclitaxel and carboplatin compared with 2 other chemotherapy doublets as a frontline therapy for patients with metastatic triple-negative breast cancer.

According to results of a phase I trial, the addition of the CDK 4/6 inhibitor palbociclib can help patients with mantle cell lymphoma overcome resistance to the BTK inhibitor&nbsp;ibrutinib.

Pembrolizumab demonstrated durable activity in 3 clinical trials in previously treated patients with mucosal melanoma.

Based on data from 2 phase III trials, the EMA&rsquo;s CHMP has recommended approval of lenalidomide as a maintenance therapy following autologous stem cell transplant for patients with newly diagnosed multiple myeloma.